Ligand Pharmaceuticals Inc (LGND)
R&D Expense Growth
582.87%
Quarterly · Period ending:
LGND R&D Expense Growth
Latest reported582.87%period ending
Latest reported582.87%period ending
LGND Quarterly R&D Growth (QoQ) (0.00% → 582.87%)
Latest values, visible window
High-resolution chart · PNG
LGND r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 582.8678% | |
| -38.8208% | |
| -83.2961% | |
| 220.07% | |
| -86.8883% | |
| 1,031.8644% | |
| -22.0264% | |
| 5.9955% | |
| -10.3333% | |
| 8.801% | |
| -0.7954% | |
| -19.288% | |
| 2.8666% | |
| 126.254% | |
| -374.6942% | |
| 9.1178% | |
| -7.7568% | |
| -49.6848% | |
| 7.7046% | |
| 6.1744% | |
| -10.7724% | |
| -18.4203% | |
| 70.5127% | |
| 0.9504% | |
| 7.0726% | |
| -36.2891% | |
| 35.8172% | |
| 12.5194% | |
| 8.185% | |
| 27.7036% | |
| 61.2256% | |
| -10.6275% | |
| -17.1729% | |
| -14.2013% | |
| 81.4037% | |
| -1.3065% | |
| -44.4022% | |
| 35.3464% | |
| 1.6336% | |
| 39.8935% | |
| 12.5624% | |
| 39.5122% | |
| 13.0812% | |
| -36.7082% | |
| 1.2115% | |
| 23.8512% | |
| 5.8921% | |
| 12.3466% | |
| -14.1169% | |
| 31.8871% | |
| -1.657% | |
| 19.3867% | |
| -17.9716% | |
| -0.4443% | |
| -6.4601% | |
| -7.1228% | |
| 1.1715% | |
| 8.4296% | |
| 5.1396% | |
| -23.6639% | |
| 62.9909% | |
| -37.0523% | |
| -36.0689% | |
| -25.2499% | |
| -10.3233% | |
| -27.2961% | |
| 2.0663% | |
| 4.7624% | |
| -9.4819% | |
| -5.4325% | |
| 79.4485% | |
| -3.3244% | |
| -10.9979% | |
| -31.3171% | |
| 6.0378% | |
| 12.4214% | |
| -43.911% | |
| 20.824% | |
| 23.3569% | |
| -24.6635% | |
| 13.7257% | |
| -12.1323% | |
| 7.6989% | |
| -11.1058% | |
| -1.432% | |
| 20.7985% | |
| -32.158% | |
| -1.0675% | |
| 7.8448% | |
| 2.2387% | |
| -6.8547% | |
| 4.9647% | |
| 1.3161% | |
| 1.6494% | |
| 4.6608% | |
| 14.3264% | |
| 4.3157% | |
| 3.873% | |
| -1.9873% | |
| -2.3425% |